2021 Reviews: Four of seven preferences require action
In 2021, JLARC staff reviewed seven tax preferences as part of its annual
reporting cycle. These include preferences for manufacturing, health insurance,
and medical cannabis.
The Legislative Auditor recommends action on four preferences
Legislative Auditor's Recommendation Extend or eliminate the
expiration date (structural purpose).
Commissioners' Recommendation Endorsed with comment
Summary
Video Summary
Legislative Auditor's Recommendation Extend and modify
Commissioners' Recommendation Endorsed
Summary
Video Summary
Legislative Auditor's Recommendation Review
Commissioners' Recommendation Endorsed with comment
Summary
Video Summary
Legislative Auditor's Recommendation Continue
Commissioners' Recommendation Endorsed with comment
Summary
Video Summary
The Legislature already implemented one recommendation during the 2021 session
Legislative Auditor's Recommendation Review and consider
whether to extend
Commissioners' Recommendation Endorsed
Summary
Video Summary
The Legislative Auditor recommends allowing one preference to expire and clarifying
the intent of another
Legislative Auditor's Recommendation Allow to expire
Commissioners' Recommendation Endorsed with comment
The Citizen Commission for Performance Measurement of Tax Preferences also considers
preferences based on information provided by the Department of Revenue. View the 2021
expedited preference report here (PDF).
Committee Action to Distribute Report
On December 1, 2021 this report was approved for distribution by the Joint
Legislative Audit and Review Committee.
Action to distribute this report does not imply the Committee agrees or disagrees
with the Legislative Auditor recommendations.
2021 Tax Preference Performance Reviews
December 2021
Joint Legislative Audit & Review Committee
More about 2021 reviews
Study questions
The Citizen Commission selected the following tax preferences for a performance
review by JLARC staff in 2021:
In addition, the Commission will consider the following tax preferences, using an
expedited process. The expedited process is primarily based on information published
by the Department of Revenue in its most recent statutorily required tax exemption
study. View the 2021 Expedited Preference Review.
2021: Not Subject to Full Review (36
Preferences)
RCW
Enacted
1
Comprehensive Cancer Centers
(Sales and Use Tax)
82.08.808; 82.12.808
2005
2
Organ Procurement (Sales and Use Tax)
82.08.02807; 82.12.02749
2002
3
Organ Procurement (B&O Tax)
82.04.326
2002
4
Ferrosilicon (Sales and Use Tax)
82.04.050(1)(a)(iv); 82.04.190(1)(d)
1986
5
Electricity Purchased by DSI
Industry (Public Utility Tax)
82.16.0495
2001
6
Natural Gas Purchased by DSI
Customers (Use Tax)
82.12.024
2001
7
Natural Gas Purchases by DSI
Industry (B&O Tax)
82.04.447
2001
8
Wax and Ceramic Materials to Create Molds
(Sales and Use Tax)
82.08.983; 82.12.983
2010
9
Free Public Hospitals (Sales and Use Tax)
82.08.02795; 82.12.02745
1993
10
Human Body Parts (Sales and Use Tax)
82.08.02806; 82.12.02748
1996
11
Prescription Drug Resellers (B&O Tax)
82.04.272
1998
12
Nebulizers (Sales and Use Tax)
82.08.803; 82.12.803
2004
13
Ostomic Items (Sales and Use Tax)
82.08.804; 82.12.804
2004
14
Comprehensive Cancer Centers (B&O Tax)
82.04.4265
2005
15
Semiconductor Materials
Manufacturing After $1 Billion Investment New Jobs Credit (B&O Tax)
82.04.448
2003
16
Semiconductor Materials
Manufacturing After $1 Billion Investment Construction Costs (Sales and Use
Tax)
82.08.965; 82.12.965
2003
17
Semiconductor Materials
Manufacturing After $1 Billion Investment Gases and Chemicals (Sales and Use
Tax)
82.08.970; 82.12.970
2003
18
Semiconductor Materials
Manufacturing After $1 Billion Investment Machinery and Equipment (Property
Tax)
84.36.645
2003
19
Semiconductor Microchip
Manufacturing After $1 Billion Investment (B&O Tax)
82.04.426
2003
20
Insurance Guarantee Association
Assessments (Insurance Premiums Tax)